Injectable Allergy Medication: The Complete Category Guide
Injectable allergy medications fall into six categories: SCIT (allergen extract, no brand, disease-modifying), biologics (Xolair, Dupixent, Tezspire), depot corticosteroids (Kenalog-40, Depo-Medrol — discouraged for routine rhinitis), and epinephrine rescue (EpiPen, Auvi-Q, neffy). SCIT is the only one with documented post-treatment remission (Durham 1999 NEJM).
5 peer-reviewed sources
The main injectable allergy medications: SCIT (custom allergen extract, no brand name, disease-modifying per Cox 2011); Xolair/omalizumab (anti-IgE, FDA 2003 + food allergy 2024); Dupixent/dupilumab (anti-IL-4Rα, FDA 2017); Tezspire/tezepelumab (anti-TSLP, FDA 2021); Kenalog-40 / Depo-Medrol (depot steroids, discouraged); EpiPen/Auvi-Q/neffy (emergency rescue only).
Why the Most Effective Injectable Allergy Treatment Is Not a Conventional Drug
When patients search for 'injectable allergy medication,' they expect a list of pharmaceutical brand names. The list exists, but the most effective injectable intervention for environmental allergies is not on it — because it isn't a conventional drug.
Subcutaneous immunotherapy (SCIT) is regulated by FDA CBER (Center for Biologics Evaluation and Research) as an allergen extract — not by FDA CDER (Center for Drug Evaluation and Research) as a pharmaceutical. There is no branded SCIT product available at a pharmacy. A physician mixes custom concentrations of allergen extract from FDA-licensed manufacturer starting material (Greer Laboratories / Stallergenes Greer, ALK-Abelló, Hollister-Stier / Jubilant HollisterStier) based on the patient's individual sensitization profile. SCIT is then injected subcutaneously in the posterior lateral upper arm, 26–27G needle, 0.05–0.5 mL volume, at weekly intervals during the build-up phase and every 2–4 weeks during maintenance, for a total 3-to-5-year course per Cox 2011 PP3 (JACI 2011;127[1 Suppl]:S1-S55, DOI 10.1016/j.jaci.2010.09.034).
Curex's at-home IgE testing with allergist review identifies the allergen sensitization profile that determines whether SCIT, sublingual immunotherapy, or a biologic injectable is the right clinical match.
The injectable medications that ARE conventional drugs — Xolair (omalizumab), Dupixent (dupilumab), Tezspire (tezepelumab-ekko) — are FDA CDER biologics with NDAs or BLAs. They control ongoing allergic disease but do not alter the underlying sensitization. SCIT is the only injectable intervention with documented post-treatment durable remission: Durham 1999 NEJM showed 3 years of SCIT produced 4 additional years of symptomatic remission after treatment was stopped.
SCIT, though the most evidence-backed injectable option, is allergen extract (CBER) not a drug (CDER). The pharmaceutical injectables — Xolair, Dupixent, Tezspire — manage disease; only SCIT produces durable post-treatment remission.
The Full Injectable Allergy Medication Matrix
Six product categories cover all injectable allergy interventions in current US practice. Each has a distinct mechanism, regulatory pathway, and clinical indication.
Custom-mixed from Greer/ALK/HollisterStier. FDA CBER (not CDER). No brand name. 3-to-5-year course. Mechanism: Treg induction, blocking IgG4, Th2 suppression. Only intervention with documented post-treatment durable remission (Durham 1999 NEJM). Indications: allergic rhinitis, allergic asthma, Hymenoptera venom allergy per Cox 2011 PP3. CPT 95115/95117 for administration, 95165 for extract preparation.
Genentech/Novartis. FDA CDER. First approved 2003 for moderate-severe allergic asthma. Added 2014 for chronic spontaneous urticaria (CSU). Added CRSwNP indication. Feb 16, 2024: IgE-mediated food allergy ≥1 yr old — first FDA approval for food allergy (OUtMATCH trial, NEJM 2024). SC q2-4 wk, dose 75–375 mg based on body weight and baseline total IgE. First 3 doses: 60-min post-injection observation (REMS requirement); subsequent doses: 30 min. Mechanism: binds free circulating IgE, blocks IgE-FcεRI binding on mast cells and basophils.
Sanofi/Regeneron. FDA CDER. First approved March 2017 for moderate-severe atopic dermatitis. October 2018: moderate-severe asthma. Additional indications: CRSwNP, eosinophilic esophagitis, prurigo nodularis, COPD. SC q2 wk. Mechanism: blocks IL-4Rα shared by both IL-4 and IL-13 signaling pathways.
AstraZeneca/Amgen. FDA approved December 17, 2021 for moderate-severe asthma. SC 210 mg q4 wk. Mechanism: binds TSLP (thymic stromal lymphopoietin), blocking upstream Th2 and innate immune cascade activation. Does not require eosinophil count or IgE for eligibility — broadest asthma biologic indication.
Kenalog-40 (triamcinolone acetonide; Bristol-Myers Squibb): FDA first approved Feb 1, 1965; IM injection; 'allergic states intractable to adequate conventional treatment.' Depo-Medrol (methylprednisolone acetate): allergic rhinitis 80–120 mg IM; relief lasts days–3 weeks. The AAAAI/ACAAI Joint Task Force Rhinitis Practice Parameter discourages routine parenteral corticosteroids for allergic rhinitis due to HPA-axis suppression, Cushing's syndrome risk, injection-site atrophy, and contraindications in diabetics/osteoporosis. These are legacy single-season symptom-relief injections, not disease-modifying.
EpiPen (Pfizer/Meridian): FDA approved 1987; IM epinephrine 0.3 mg (adult) or 0.15 mg (Jr); outer thigh injection. Auvi-Q (kaléo): FDA approved 2012; reintroduced 2017; audible injection instructions. neffy (ARS Pharma): FDA approved August 9, 2024 — first needle-free epinephrine; intranasal spray 2 mg; age ≥4 yr ≥15 kg; pediatric 1 mg approved March 5, 2025. Epinephrine is RESCUE for anaphylaxis, not a treatment for allergy — it reverses acute mast-cell degranulation cascade but does not modify the underlying sensitization.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Evidence Comparison for Injectable Allergy Medications
The evidence base varies substantially across categories. SCIT holds the largest body of randomized controlled evidence for aeroallergen-driven allergic rhinitis.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youInjectable Allergy Medication Comparison by Clinical Goal
Choose based on clinical goal, not product category:
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT | 3–5 years | ||||
Xolair | Ongoing (not disease-modifying) | ||||
Dupixent | Ongoing (not disease-modifying for allergy sensitization) | ||||
Tezspire | Ongoing | ||||
Kenalog-40 / Depo-Medrol | Weeks | ||||
EpiPen / neffy | Single-use rescue |
- Efficacy
- Duration
- 3–5 years
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Ongoing (not disease-modifying)
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Ongoing (not disease-modifying for allergy sensitization)
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Ongoing
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Weeks
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Single-use rescue
- Cost (5yr)
- Convenience
- Safety
Curex delivers SCIT itself — the allergen-extract injection — at home for $129/month, replacing the 39-visit Year 1 clinic schedule with one weekly shot you give yourself. The personalized serum is sterile-compounded to USP <797>, a board-certified allergist oversees the plan, a prescribed epinephrine auto-injector is confirmed on hand before the first dose, and your first injection and every dose change are supervised live over Zoom — the same Treg-induction, blocking-IgG4 tolerance, now self-administered at home.
See if at-home shots are right for youFrequently asked questions
What injectable medications treat allergies?
Six categories: (1) SCIT — allergen extract, custom-mixed, no brand name, disease-modifying; (2) Xolair (omalizumab) — anti-IgE biologic, SC, FDA 2003+; (3) Dupixent (dupilumab) — anti-IL-4Rα biologic; (4) Tezspire (tezepelumab-ekko) — anti-TSLP biologic, FDA Dec 2021; (5) Kenalog-40 / Depo-Medrol — depot corticosteroids (discouraged for routine rhinitis); (6) EpiPen / Auvi-Q / neffy — emergency epinephrine only.
Is SCIT considered a medication?
Not in the conventional pharmaceutical sense. SCIT is an allergen extract regulated by FDA CBER (biologics), not FDA CDER (drugs). It has no brand name, is custom-mixed per patient, and is not dispensed by a pharmacy.
What injectable allergy medication is available in 2024?
As of 2024: SCIT (extracts, unchanged), Xolair (expanded Feb 16, 2024 for IgE food allergy — OUtMATCH trial), Dupixent (multiple indications), Tezspire (severe asthma, FDA Dec 2021), neffy nasal epinephrine (FDA Aug 9, 2024 — first needle-free epinephrine).
Can I stop Xolair after a few years and maintain the benefit?
No. Xolair's benefits stop when the medication is discontinued — it does not produce the durable post-treatment remission that SCIT does. SCIT is the only injectable allergy intervention with documented 4+ years of remission after stopping treatment (Durham 1999 NEJM).
Why do guidelines discourage depot steroid injections for allergies?
Kenalog-40 and Depo-Medrol suppress HPA-axis function with repeated use, carry risks of Cushing's syndrome, osteoporosis, injection-site subcutaneous atrophy, and are contraindicated in poorly controlled diabetes. The AAAAI/ACAAI Joint Task Force Rhinitis Practice Parameter discourages routine parenteral corticosteroids for allergic rhinitis precisely because safer evidence-based options (antihistamines, nasal steroids, SCIT) exist.
Related Articles
Allergy Desensitization Shots Guide | Curex
Allergy desensitization shots are the 20th-century term for SCIT. Cochrane 2007 (51 RCTs) found symptom SMD -0.73. Learn the current terminology and evidence.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Test Shots vs Treatment: CPT Codes | Curex
Allergy test shots (CPT 95004 prick, CPT 95024 intradermal) diagnose sensitization in one visit. Treatment shots (SCIT, CPT 95115/95117) are a 3-5 year immunotherapy course.
Read moreWhere To Get Allergy Shots | Curex Allergy Shot Guide
Get allergy shots at an allergist office or at home with Curex SCIT ($129/mo). HOPD sites can bill $24,400 for what a freestanding clinic charges $1,827.
Read moreBefore and After Allergy Shots | Curex Guide
Meaningful relief from allergy shots arrives at 6-12 months, not 6 weeks. Durham 1999 NEJM shows 7-12 yr durable remission after a 3-yr course — if you finish it.
Read moreDesensitization Therapy Allergy: SCIT Guide | Curex
Desensitization therapy for allergy is the older term for SCIT — confirmed by Noon 1911 Lancet. Different from drug desensitization. Cochrane 2007: symptom SMD -0.73.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.